Back to top
more

Sientra, Inc. (SIEN)

(Delayed Data from NSDQ)

$8.40 USD

8.40
1,311,608

-0.66 (-7.28%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.41 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Ambrx Biopharma (AMAM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Ambrx Biopharma Inc. Sponsored ADR (AMAM) and Sientra (SIEN) have performed compared to their sector so far this year.

Sientra (SIEN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sientra (SIEN) delivered earnings and revenue surprises of 3.41% and 7.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of -29.41% and 12.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 13.04% and 2.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Fast-paced Mover Sientra (SIEN) Is a Great Choice for Value Investors

by Zacks Equity Research

Sientra (SIEN) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Despite Fast-paced Momentum, Sientra (SIEN) Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sientra (SIEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Steris (STE) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of 6.98% and 8.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 2.56% and 2.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sientra (SIEN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sientra (SIEN) delivered earnings and revenue surprises of -137.50% and 2.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 12.50% and 0.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Sientra (SIEN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aspira (AWH) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aspira (AWH) delivered earnings and revenue surprises of 33.33% and 10.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Silk Road Medical (SILK) delivered earnings and revenue surprises of 8.11% and 7.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 5.36% and 5.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Inc. (STXS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 19.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 58.14% and 12.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of -100% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sientra (SIEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sientra (SIEN) delivered earnings and revenue surprises of -11.54% and 5.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 12.50% and 18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in LENSAR, Inc. (LNSR): Can Its 5.3% Jump Turn into More Strength?

by Zacks Equity Research

LENSAR, Inc. (LNSR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Sientra (SIEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sientra (SIEN) delivered earnings and revenue surprises of -42.11% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Sientra (SIEN) This Earnings Season?

by Zacks Equity Research

Sientra (SIEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sientra (SIEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sientra (SIEN) delivered earnings and revenue surprises of -153.85% and 8.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Sientra (SIEN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sientra (SIEN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sientra (SIEN) delivered earnings and revenue surprises of 4.35% and -0.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?